HOUSTON, TX (February 27, 2014) - Houston-based Procyrion, Inc. has been recognized by the Rice Alliance as a “Top Life Science Company” at the 2014 Texas Life Science Forum for its Aortix™, the first catheter-deployed circulatory assist device intended for long-term use in the treatment of chronic heart failure. Only ten of 55 presenting companies specializing in medical technologies and pharma received this designation.
A group of investors, industry experts and business leaders from around the country selected the top ten presenting companies based on product and service offering, unique differentiators, market opportunity and strength and experience of the management team.
Procyrion’s Aortix™ device, conceived by Dr. Reynolds M. Delgado III, Medical Director of Mechanical Support at the Texas Heart Institute, is a percutaneous intra-aortic continuous flow pump delivered by a catheter inserted through the femoral artery and held in place using novel self-expanding anchors. The small size and unique design of the device enable a minimally invasive outpatient procedure that takes about ten minutes to complete.
“Every year the quality of companies improves," said Rice Alliance Managing Director Brad Burke, who announced the winners at the event. "This year we had a diversity of companies including rapid, in-office diagnosis of ENT illnesses to a catheter-based, minimally-invasive heart pump for the treatment of chronic heart failure. As a group, the companies this year are further along which makes them more appealing to current investors, who have commented on the improved quality of the companies."
The 3rd annual Texas Life Science Forum, hosted by the Rice Alliance for Technology and Entrepreneurship and BioHouston and Texas Healthcare and BioScience, is the largest life science venture capital conference in the Southwest. The event featured more than 70 industry and investment speakers and attracted more than 600 attendees.
Procyrion’s team of life science entrepreneurs, cardiologists and circulatory support experts have also been accepted to present Aortix at the American College of Cardiology’s 64th Annual Scientific Session & Expo in Washington D.C. March 29 - 31, 2014 and the International Society for Heart and Lung Transplantation’s 34th Annual Meeting & Scientific Session in San Diego April 10 – 13, 2014.
Houston-based medical device firm Procyrion, Inc. is developing the first catheter-deployed, intra-aortic pump for ambulatory use. The device is designed to rest and heal the heart by reducing afterload while simultaneously improving blood flow to vital organs. This groundbreaking cardiology tool, conceived by cardiologist Dr. Reynolds M. Delgado, III, medical director of Mechanical Support Devices in Heart Failure at the Texas Heart Institute, is expected to provide a minimally invasive treatment option for millions of chronic heart failure patients. For more information, call 713.579.9227.